The activity of IO agents in luminal breast cancers is more limited with response rates ranging from 11% to 30% for pembrolizumab in patients with advanced PD-L1 positive, HR-positive HER2-negative breast cancer and 3% with avelumab in a similar patient population (19, 20). This evidence concerns the gene ERBB2 and breast carcinoma.